423 related articles for article (PubMed ID: 10335419)
1. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C; Gautier JF; Danforth E
Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
[TBL] [Abstract][Full Text] [Related]
2. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
de Souza CJ; Burkey BF
Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
[TBL] [Abstract][Full Text] [Related]
3. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes.
Arch JR; Wilson S
Int J Obes Relat Metab Disord; 1996 Mar; 20(3):191-9. PubMed ID: 8653138
[TBL] [Abstract][Full Text] [Related]
4. Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat.
Umekawa T; Yoshida T; Sakane N; Saito M; Kumamoto K; Kondo M
Eur J Endocrinol; 1997 Apr; 136(4):429-37. PubMed ID: 9150705
[TBL] [Abstract][Full Text] [Related]
5. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist.
Nagase I; Yoshida T; Kumamoto K; Umekawa T; Sakane N; Nikami H; Kawada T; Saito M
J Clin Invest; 1996 Jun; 97(12):2898-904. PubMed ID: 8675704
[TBL] [Abstract][Full Text] [Related]
6. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice.
Kiso T; Namikawa T; Tokunaga T; Sawada K; Kakita T; Shogaki T; Ohtsubo Y
Biol Pharm Bull; 1999 Oct; 22(10):1073-8. PubMed ID: 10549858
[TBL] [Abstract][Full Text] [Related]
7. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism.
Collins S; Cao W; Robidoux J
Mol Endocrinol; 2004 Sep; 18(9):2123-31. PubMed ID: 15243132
[TBL] [Abstract][Full Text] [Related]
8. Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice.
Collins S; Daniel KW; Petro AE; Surwit RS
Endocrinology; 1997 Jan; 138(1):405-13. PubMed ID: 8977430
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
Maruyama T; Seki N; Onda K; Suzuki T; Kawazoe S; Hayakawa M; Matsui T; Takasu T; Ohta M
Bioorg Med Chem; 2009 Aug; 17(15):5510-9. PubMed ID: 19581100
[TBL] [Abstract][Full Text] [Related]
10. Evidence for numerous brown adipocytes lacking functional beta 3-adrenoceptors in fat pads from nonhuman primates.
Viguerie-Bascands N; Bousquet-Mélou A; Galitzky J; Larrouy D; Ricquier D; Berlan M; Casteilla L
J Clin Endocrinol Metab; 1996 Jan; 81(1):368-75. PubMed ID: 8550779
[TBL] [Abstract][Full Text] [Related]
11. Thermogenesis and related metabolic targets in anti-diabetic therapy.
Arch JR
Handb Exp Pharmacol; 2011; (203):201-55. PubMed ID: 21484574
[TBL] [Abstract][Full Text] [Related]
12. [Beta 3 adrenergic receptor polymorphism and obesity].
Yoshida T; Umekawa T
Nihon Rinsho; 1998 Jul; 56(7):1871-5. PubMed ID: 9702068
[TBL] [Abstract][Full Text] [Related]
13. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
14. The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice.
Fu L; Isobe K; Zeng Q; Suzukawa K; Takekoshi K; Kawakami Y
Eur J Pharmacol; 2008 Apr; 584(1):202-6. PubMed ID: 18304529
[TBL] [Abstract][Full Text] [Related]
15. Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor.
Fletcher DS; Candelore MR; Grujic D; Lowell BB; Luell S; Susulic VS; Macintyre DE
J Pharmacol Exp Ther; 1998 Nov; 287(2):720-4. PubMed ID: 9808702
[TBL] [Abstract][Full Text] [Related]
16. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats.
Ghorbani M; Himms-Hagen J
Int J Obes Relat Metab Disord; 1997 Jun; 21(6):465-75. PubMed ID: 9192230
[TBL] [Abstract][Full Text] [Related]
17. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
Arch JR
Eur J Pharmacol; 2002 Apr; 440(2-3):99-107. PubMed ID: 12007528
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Advances in pharmacotherapy for obesity.
Carruba M; Tomello C; Briscini L; Nisoli E
Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
[TBL] [Abstract][Full Text] [Related]
20. Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.
Yen TT
Obes Res; 1994 Sep; 2(5):472-80. PubMed ID: 16353599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
